The Myeloma Institute for Research and Therapy is one of the largest centers in the world for research and clinical care related to multiple myeloma and related disorders. It is committed to accelerating curative therapies. With a team of leading scientists and clinicians, the Myeloma Institute translates advances in the laboratory to breakthrough clinical treatments.
Founded in 1989 by Dr. Bart Barlogie, the myeloma program at the University of Arkansas for Medical Sciences has seen more than 10,000 patients from every state in the United States and more than 50 foreign countries (click here for map) and has performed more than 9,000 peripheral blood stem cell transplants. Dr. Barlogie and his colleagues have fundamentally changed the course of the disease through novel diagnostic procedures and therapeutic interventions. The quality of our innovative clinical and basic science research is known nationally and internationally.
MIRT is the only facility in the world that routinely offers Gene Array Analysis for newly referred patients and utilizes this information for patient management and planning of therapy.
The Myeloma Institute was the first to:
- use tandem bone marrow/peripheral blood stem cell transplants
- perform transplants on an outpatient basis
- safely transplant patients age 70 and above
- transplant patients with renal disease
- introduce thalidomide as anti-angiogenesis therapy
- and many more
The hallmark of the Myeloma Institute is a program of well-designed clinical trials that challenge the traditional body of thought on disease treatment in order to improve outcomes. Only large research centers have the necessary resources to be able to offer clinical trials and thereby enable patients to benefit from innovative, cutting-edge care. The Myeloma Institute is unique in that it has longer follow-up on more patients than other facilities. This provides the large amount of statistically valid data critical for developing curative therapies.
The Myeloma Institute's proactive approach has yielded many significant therapeutic advances in multiple myeloma:
Our specialized and experienced staff provides superb medical attention in an atmosphere of friendliness and compassion. We provide our patients with a thorough understanding of their illness and develop treatment plans aimed at delivering long-term disease control with a high quality of life and, ultimately, cure. The Institute’s programs are recognized as outstanding by the National Cancer Institute and the Southwest Oncology Group. We are the primary investigating institution on numerous clinical trials for these groups.
Our Academic Home
The Myeloma Institute is a Chancellor's Center of Excellence at the University of Arkansas for Medical Sciences (UAMS). It is housed in the Winthrop P. Rockefeller Cancer Institute. The UAMS Campus includes a 350-bed teaching hospital; the Jackson T. Stephens Spine & Neurosciences Institute; the Winthrop P. Rockefeller Cancer Institute; the Harvey and Bernice Jones Eye Institute; the Outpatient Center; the Donald W. Reynolds Center on Aging; and a host of related clinical services. UAMS physicians are faculty members of the University’s College of Medicine. Many are active in basic and clinical research. They are also active in teaching medical students, residents and fellows (physicians in training).